About Glyoxylate reductase/hydroxypyruvate reductase
Glyoxylate reductase/hydroxypyruvate reductase (GRHPR) is a protein
from Homo sapiens identified by UniProt accession
Q9UBQ7, 328 residues long.
MolForge cross-references it against 0 known binders and
206 disease associations.
Target properties
| Protein name | Glyoxylate reductase/hydroxypyruvate reductase |
| UniProt accession | Q9UBQ7 |
| Gene | GRHPR |
| Organism | Homo sapiens |
| Length | 328 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (206)
Diseases linked to this target (Open Targets).
- primary hyperoxaluria type 2 · score 0.78
- primary hyperoxaluria · score 0.58
- nephrolithiasis · score 0.38
- nephrocalcinosis · score 0.33
- Nephrocalcinosis · score 0.19
- primary hyperoxaluria type 3 · score 0.09
- nephrolithiasis, calcium oxalate, 2, with or without nephrocalcinosis · score 0.07
- nephrotic syndrome · score 0.07
- daytime rest measurement · score 0.07
- familial idiopathic steroid-resistant nephrotic syndrome · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UBQ7-F1 | alphafold | PREDICTED | 96.89 | — |
Amino-acid sequence (328 residues)
MRPVRLMKVF VTRRIPAEGR VALARAADCE VEQWDSDEPI PAKELERGVA GAHGLLCLLS DHVDKRILDA AGANLKVIST MSVGIDHLAL DEIKKRGIRV GYTPDVLTDT TAELAVSLLL TTCRRLPEAI EEVKNGGWTS WKPLWLCGYG LTQSTVGIIG LGRIGQAIAR RLKPFGVQRF LYTGRQPRPE EAAEFQAEFV STPELAAQSD FIVVACSLTP ATEGLCNKDF FQKMKETAVF INISRGDVVN QDDLYQALAS GKIAAAGLDV TSPEPLPTNH PLLTLKNCVI LPHIGSATHR TRNTMSLLAA NNLLAGLRGE PMPSELKL
Explore Glyoxylate reductase/hydroxypyruvate reductase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets